C-terminal heparin-binding peptide of snake venom VEGF specifically blocks VEGF-stimulated endothelial cell proliferation

Pathophysiology of Haemostasis and Thrombosis

Volumn 34, Issue 4-5, 2006, Pages 197-199

  Yamazaki, Yasuo ^a   Tokunaga, Yuko ^a   Takani, Koji ^a   Morita, Takashi ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Heparin; Heparin binding peptide; KDR binding protein; Lys49PLA2; Snake venom; Vascular endothelial growth factor

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BINDING PROTEIN; ENZYME VARIANT; HEPARAN SULFATE; HEPARIN; HEPARIN BINDING PROTEIN; KINASE DOMAIN CONTAINING RECEPTOR; LYSINE; PHOSPHOLIPASE A2; RECEPTOR; SNAKE VENOM; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN F; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 BINDING PROTEIN; VIPER VENOM;

AGKISTRODON PISCIVORUS PISCIVORUS; ANIMAL CELL; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CONFERENCE PAPER; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MITOGENESIS; MOLECULAR RECOGNITION; MUSCLE TOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN VARIANT; RECEPTOR BINDING; RECEPTOR BLOCKING; SEQUENCE ANALYSIS; SNAKE; TOXICITY;

ANIMALS; BINDING SITES; CELL PROLIFERATION; ENDOTHELIAL CELLS; HEPARIN; HUMANS; KINETICS; PEPTIDE FRAGMENTS; SNAKE VENOMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33646772894     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092423     Document Type: Conference Paper

References (11)

1. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
2. Yamazaki Y, Takani K, Atoda H, Morita T: Snake venom vascular endothelial growth factors (VEGFs) exhibit potent activity through their specific recognition of KDR (VEGF receptor 2). J Biol Chem 2003;278:51985-51988.
3. Suto K, Yamazaki Y, Morita T, Mizuno H: Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms: insight into selective VEGF binding to kinase insert domain-containing receptor but not to fms-like tyrosine kinase-1. J Biol Chem 2005;280:2126-2131.
4. Tessler S, Rockwell P, Hicklin D, Cohen T, Levi BZ, Witte L, Lemischka IR, Neufeld G: Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. J Biol Chem 1994;269:12456-12461.
5. Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N: The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996;271:7788-7795.
6. Yamazaki Y, Tokunaga Y, Takani K, Morita T: Identification of heparin-binding region of snake venom vascular endothelial growth factor (VEGF-F) and its blocking of VEGF-A165. Biochemistry 2005;44:8858-8864.
7. Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL: Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 2000;407:1029-1034.
8. Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze GJ Jr: Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis 1993;4:661-669.
9. Lomonte B, Angulo Y, Calderon L: An overview of lysine-49 phospholipase A2 myotoxins from crotalid snake venoms and their structural determinants of myotoxic action. Toxicon 2003;42:885-901.
10. Gutierrez JM, Ownby CL: Skeletal muscle degeneration induced by venom phospholipases A2: insights into the mechanisms of local and systemic myotoxicity. Toxicon 2003;42:915-931.
11. 2. J Biol Chem 2005;280:29989-29992.